Smith, Moore & Co’s AbbVie ABBV Stock Holding History

Smith, Moore & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.36M	Buy	29,261 +1,659	+6%	+$368K	0.46%	48
2025 Q4	$6.31M	Sell	27,602 -1,502	-5%	-$342K	0.48%	45
2025 Q3	$6.74M	Buy	29,104 +431	+2%	+$87.8K	0.52%	40
2025 Q2	$5.32M	Sell	28,673 -951	-3%	-$177K	0.45%	46
2025 Q1	$6.21M	Sell	29,624 -627	-2%	-$122K	0.57%	31
2024 Q4	$5.38M	Buy	30,251 +88	+0.3%	+$16.2K	0.49%	45
2024 Q3	$5.96M	Sell	30,163 -1,837	-6%	-$343K	0.57%	34
2024 Q2	$5.49M	Sell	32,000 -1,385	-4%	-$229K	0.57%	33
2024 Q1	$6.08M	Sell	33,385 -1,734	-5%	-$299K	0.65%	27
2023 Q4	$5.44M	Sell	35,119 -757	-2%	-$110K	0.64%	25
2023 Q3	$5.35M	Buy	35,876 +450	+1%	+$66.1K	0.71%	26
2023 Q2	$4.77M	Sell	35,426 -604	-2%	-$88.6K	0.61%	32
2023 Q1	$5.74M	Sell	36,030 -1,884	-5%	-$288K	0.78%	26
2022 Q4	$6.13M	Sell	37,914 -514	-1%	-$78.8K	0.85%	23
2022 Q3	$5.16M	Sell	38,428 -1,243	-3%	-$178K	0.78%	23
2022 Q2	$6.08M	Sell	39,671 -829	-2%	-$127K	0.94%	18
2022 Q1	$6.57M	Sell	40,500 -889	-2%	-$129K	0.9%	18
2021 Q4	$5.6M	Buy	41,389 +892	+2%	+$105K	0.78%	19
2021 Q3	$4.37M	Buy	40,497 +282	+0.7%	+$32.2K	0.67%	25
2021 Q2	$4.53M	Buy	40,215 +2,109	+6%	+$238K	0.68%	22
2021 Q1	$4.12M	Sell	38,106 -902	-2%	-$96.5K	0.67%	23
2020 Q4	$4.18M	Buy	39,008 +683	+2%	+$65.6K	0.78%	22
2020 Q3	$3.36M	Buy	38,325 +2,239	+6%	+$211K	0.7%	33
2020 Q2	$3.54M	Buy	36,086 +3,858	+12%	+$340K	0.78%	27
2020 Q1	$2.46M	Sell	32,228 -377	-1%	-$32.1K	0.65%	34
2019 Q4	$2.89M	Buy	32,605 +1,602	+5%	+$133K	0.6%	35
2019 Q3	$2.35M	Sell	31,003 -4,576	-13%	-$314K	0.52%	40
2019 Q2	$2.59M	Buy	35,579 +880	+3%	+$69.2K	0.58%	36
2019 Q1	$2.8M	Buy	34,699 +2,732	+9%	+$224K	0.67%	33
2018 Q4	$2.95M	Buy	31,967 +72	+0.2%	+$6.33K	0.8%	26
2018 Q3	$8.63M	Buy	31,895 +2,598	+9%	+$246K	1.97%	8
2018 Q2	$2.71M	Buy	29,297 +1,303	+5%	+$127K	0.68%	27
2018 Q1	$2.65M	Sell	27,994 -2,320	-8%	-$255K	0.71%	28
2017 Q4	$2.93M	Buy	30,314 +1,583	+6%	+$149K	0.79%	27
2017 Q3	$2.55M	Buy	28,731 +1,484	+5%	+$113K	0.73%	28
2017 Q2	$1.98M	Buy	27,247 +595	+2%	+$40K	0.66%	33
2017 Q1	$1.74M	Buy	26,652 +353	+1%	+$22.2K	0.62%	36
2016 Q4	$1.65M	Sell	26,299 -426	-2%	-$26K	0.63%	38
2016 Q3	$1.69M	Sell	26,725 -1,443	-5%	-$93.4K	0.68%	33
2016 Q2	$1.74M	Buy	28,168 +3,578	+15%	+$218K	0.72%	28
2016 Q1	$1.41M	Buy	24,590 +2,998	+14%	+$167K	0.61%	36
2015 Q4	$1.28M	Buy	21,592 +2,834	+15%	+$163K	0.64%	31
2015 Q3	$1.02M	Buy	18,758 +2,860	+18%	+$186K	0.57%	29
2015 Q2	$1.07M	Buy	15,898 +55	+0.3%	+$3.59K	0.54%	29
2015 Q1	$927K	Buy	15,843 +36	+0.2%	+$2.17K	0.49%	35
2014 Q4	$1.03M	Sell	15,807 -200	-1%	-$12.6K	0.55%	33
2014 Q3	$925K	Buy	16,007 +4,457	+39%	+$247K	0.52%	37
2014 Q2	$652K	Sell	11,550 -5,371	-32%	-$282K	0.4%	42
2014 Q1	$870K	Sell	16,921 -670	-4%	-$33.9K	0.52%	35
2013 Q4	$929K	Buy	+17,591	New	+$865K	0.58%	32

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Smith, Moore & Co's ABBV Position: Q1 2026 in Review

Smith, Moore & Co increased its AbbVie (ABBV) stake by 6% in Q1 2026, buying an estimated $368K and bringing the position to 29,261 shares worth $6.36M. The position accounts for 0.46% of the portfolio, ranked #48.

Smith, Moore & Co first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $8.63M in Q3 2018. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Smith, Moore & Co held 29,261 shares of AbbVie worth $6.36M as of Q1 2026.
Smith, Moore & Co bought 1,659 AbbVie shares in Q1 2026, an estimated $368K.
AbbVie made up 0.46% of Smith, Moore & Co's portfolio in Q1 2026, its #48 holding.
Smith, Moore & Co first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
Smith, Moore & Co's AbbVie position peaked at $8.63M in Q3 2018.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.